The company delivered a robust performance in Q2FY26 with consolidated revenue of ₹216.53 crore, registering a strong 22% year-on-year growth, led by continued momentum in the Pathology segment which grew 24% YoY. Normalized EBITDA rose sharply by 49% YoY to ₹75.36 crore, reflecting improved operating leverage, cost efficiencies, and business mix optimization. Profit After Tax surged 82% YoY to ₹47.90 crore, underscoring the company’s focus on profitable growth. Gross margin remained strong at 72%, with an EBITDA margin of 33%. The company continues to maintain a healthy balance sheet, remaining debt-free on a consolidated basis and holding net cash and short-term investments exceeding ₹190 crore. In recognition of its strong financial performance and in line with its commitment to shareholder value creation, the Board of Directors has declared an interim dividend of ₹7 per equity share (of ₹10 face value each, pre-bonus) with 24-October-2025 as the record date, and approved a bonus issue in the ratio of 2:1, subject to statutory, regulatory, and shareholder approval. The proposed bonus issue underscores the company’s consistent performance, confidence in its long-term growth trajectory, and commitment to reward shareholders while enhancing stock liquidity and expanding retail participation
India’s largest diagnostic test volume processor further strengthened its leadership position during the quarter, processing an all-time high of 53.3 million tests up 21% year-on-year. The Pathology business maintained strong traction with franchise revenue up 20% and partnership revenue up 35% year-on-year. During H1FY26, four new laboratories were added in Vijayawada, Bhagalpur, Roorkee, and Kashmir, further deepening regional penetration and enhancing service accessibility.
Senior management remarks:
“We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India” – Rahul Guha, MD & CEO, Thyrocare Technologies Ltd
“We are delighted with Thyrocare’s strong Q2FY26 performance, which reflects the strength of our business fundamentals, disciplined financial management, and the unwavering commitment of our teams. As we mark 25 years of trust and innovation, the bonus share announcement underscores our commitment to our shareholders and investors, and reinforces confidence in our long-term growth journey” – Alok Kumar Jagnani Group CFO
